TT304: 2019 year end accounts (FRS102 update)

With 2019 almost at a close, and attention turning shortly to year-end numbers, accounts preparers should be aware of important changes to FRS102 now effective. In December 2017, the Financial Reporting Council (FRC) concluded their triennial review of new UK GAAP (FRS102) by publishing amendments to FRS 102 The Financial Reporting Standard applicable in the UK […]

Duncan StannettPartner, Barnes Roffe LLP

TT303: Cracking down on compliance pays for HMRC

New figures show HMRC’s “customer compliance” efforts are yielding substantial sums.  In early August, HMRC issued its annual report and accounts for 2018/19. While its 301 pages are not everyone’s choice of holiday reading, it did contain some eye-opening information about the “compliance yield” – how much HMRC raised from its work in countering tax […]

Duncan StannettPartner, Barnes Roffe LLP

TT302: Well-being at the heart of recruitment and retention

People always aspire towards achieving the elusive ‘work-life balance’, but in 2019 it’s increasingly an expectation as employees look to their workplace for more than just salary and perks. A survey by Accountancy Age, in October last year, revealed that UK workers spend almost 3,515 days at work during their lifetime. This will include on […]

Duncan StannettPartner, Barnes Roffe LLP

eureos gmbh steuerberatungsgesellschaft rechtsanwaltsgesellschaft joins IR as the exclusive Corporate Finance Member in Germany

IR Global, the world’s largest exclusive network of advisory firms is delighted to introduce Arell Buchta of eureos gmbh steuerberatungsgesellschaft rechtsanwaltsgesellschaft. Arell has joined IR as our exclusive Corporate Finance Member in Germany. eureos is a company composed of experienced attorneys, tax consultants, corporate consultants and auditors. Our consultants bring with them the comprehensive experience and sound expertise […]

Inhibitec Antibodies, S.L. Cantabrian biotechnology company has developed a monoclonal antibody for a new therapeutic target

Inhibitec Antibodies, S.L. Cantabrian biotechnology company, a spin-off of the CSIC and University of Cantabria, has developed a monoclonal antibody for a new therapeutic target. Last week,  it was in Cambridge, within the Idea Spark Program designed by MIT and SODERCAN. A significant number of psoriatic patients with the severe disease do not respond to […]

Jean-François AlandryCEO & Founder, You Are Capital